Back

Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2

Luczkowiak, J.; Radreau, P.; Nguyen, L.; Labiod, N.; Lasala, F.; Herbreteau-Delale, C.; Delgado, R.

2022-02-23 microbiology
10.1101/2022.02.21.481341 bioRxiv
Show abstract

Using a polyclonal approach of equine anti-SARS-CoV-2 F(ab)2 antibodies we have achieved a high level of neutralizing potency against all SARS-CoV-2 variants tested. Neutralization titers were in the range of 105-106 IU/mL including Omicron: 111,403 UI/mL, which is 2-3 orders of magnitude what is normally achieved in response to SARS-CoV-2 infection and/or vaccination. The presence of high titers of a repertoire of antibodies targeting conserved epitopes in different regions of the spike protein could plausibly account for this remarkable breadth of neutralization. These results warrant the clinical investigation of anti-SARS-CoV-2 equine polyclonal F(ab)2 antibodies as a novel therapeutic strategy against COVID-19

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.